



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

## Emicizumab

Cat. No.:	HY-P9940
CAS No.:	1610943-06-0
Target:	Factor VIII
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL<sup>[1]</sup>.</p> <p>Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>FVIII-deficient mice<sup>[1]</sup></td></tr><tr><td>Dosage:</td><td>1.5-10 mg/kg</td></tr><tr><td>Administration:</td><td>IV, 24 hours before tail-clip bleeding was performed</td></tr><tr><td>Result:</td><td>Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.</td></tr></table>	Animal Model:	FVIII-deficient mice <sup>[1]</sup>	Dosage:	1.5-10 mg/kg	Administration:	IV, 24 hours before tail-clip bleeding was performed	Result:	Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.
Animal Model:	FVIII-deficient mice <sup>[1]</sup>								
Dosage:	1.5-10 mg/kg								
Administration:	IV, 24 hours before tail-clip bleeding was performed								
Result:	Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.								

### REFERENCES

[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. *Blood*. 2020 Aug 6;136(6):740-748.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA